Kornimate/medical-research-clean huggingface dataset:
ipt-based group intervention by non-specialist for improvement of depressive symptoms in community young adults in brazil

Conditions: Depression; Interpersonal Relations

Summary: major depressive disorder is a highly prevalent, recurrent, and debilitating disease, the third cause of years of lost life in the world, and it may be the most common disease in 2030, according to the world health organization (who). furthermore, it's also related to decreased quality of life and high mortality. interpersonal psychotherapy (ipt) is a first-line treatment and can also be used for the prevention of depression. this randomized controlled clinical trial is planned to have 50 participants randomized between an interventional and a control group (waiting list). our study covers young adults (18 to 24 years old) with depression. participants will be invited by social media to undergo treatment in an ipt group. the intervention group will be separated into groups with up to 10 participants, with a weekly meeting for eight weeks. the intervention will focus on interpersonal relationships within the model of ipt and will be held by a university student and a doctor trained in ipt.


Eligibility criteria:
inclusion criteria: * young adults (between 18 and 24 years old) * young adults who work, live or study in porto alegre * phq ≥ 5 - without suicide ideation exclusion criteria: * maniac or hypomanic episode * psychotic syndrome * substance abuse * suicide risk or ideation
duration of antibiotics in infective exacerbations of cystic fibrosis

Conditions: Cystic Fibrosis

Summary: cystic fibrosis patients attending with infective exacerbations will be enrolled into the study. the trial is a double blinded, randomised trial with patients randomised to 10,14 or 21 days of antibiotic therapy, comprising of tobramycin and either ceftazidime or meropenem.


Eligibility criteria:
inclusion criteria: * 16 years or older * diagnosis of cystic fibrosis * presenting with infective exacerbation exclusion criteria: * unable to give consent * allergy to study medications * intolerance of aminoglycoside antibiotics * pseudomonas resistant to study antibiotics * on the active transplant list or fev1\<20% predicted * pregnancy/breast-feeding * co-existent abpa requiring a change in treatment * co-existent mycobacterial infection * a previous participant in the study
long term clinical outcome of single open door laminoplasty with preservation of unilateral muscular ligament complex

Conditions: Cervical Myelopathy

Summary: to collect and measure the preoperative and postoperative clinical data of the patients undergoing single open-door expansive laminoplasty with preservation of musclar ligament complex through posterior cervical approach in our hospital and summarize the long-term clinical effect and postoperative imaging changes and analyze the long-term clinical effect of this operation

objective: to collect and measure the preoperative and postoperative clinical data of the patients undergoing single open-door expansive laminoplasty with preservation of musclar ligament complex through posterior cervical approach in our hospital. to summarize the long-term clinical effect and postoperative imaging changes and to analyze the long-term clinical effect of this operation on cervical spondylosis. to provide scientific basis for clinical work and theoretical research in the future. this study was a retrospective study, and the medical records of posterior cervical open-door expansive laminoplasty with musclar ligament complex preservation in the orthopedics department of our hospital from 2006 to 2017 were collected, and the patients with complete diagnosis and treatment data were selected for analysis and research.the preoperative and postoperative changes of the patients were studied by combining the patient's case and imaging examination (mr, ct, x plain film) and other diagnosis and treatment data.

Eligibility criteria:
inclusion criteria: 1. age 18-70, gender unlimited; 2. the patient was diagnosed with cervical spondylosis and met the indications of posterior cervical laminoplasty; 3. basis of serious diseases of heart, brain, lung, kidney or other important organs, preoperative asa score i-ii; 4. agree to participate in the study and sign the informed consent； exclusion criteria: 1. preoperative asa score ≥iii; 2. one-stage combined anterior and posterior surgery of cervical spine; 3. correction of cervical deformity; 4. patients with gastric emptied disorders (such as gastroesophageal reflux, chronic history of aspiration, delayed gastric emptied), complete obstruction of the digestive tract, and inability to use enteral preparations; 5. patients with high risk conditions, such as severe cardio-renal insufficiency, affecting the safety evaluation of the trial; 6. people with mental disorders, alcohol dependence or drug abuse history; 7. women in the period of lactation and pregnancy; 8. people with allergic constitution or previous allergies to a variety of drugs; 9. other researchers consider it inappropriate to participate in this study

Keywords: open door laminoplasty preservation of unilateral muscular ligament complex
alternative haemodiafiltration in summer season for chronic kidney disease patients

Conditions: Sweating

Summary: hemodiafiltration is a renal replacement technique combining diffusion and convection to enhance solute removal. post dialyser replacement fluid is administered to achieve the target fluid balance. the skin is the largest human organ playing an important role in thermal and na regulation and skin blood flow is 8.5-10%of cardiac output .

sweat contains electrolytes, creatinine and urea, with higher excretion by mild physical exercise. these findings motivate studies investigating the effect of stimulated sweating on volume control in kidney disease patients. using sweat as the vehicle for removing molecules normally excreted in the urine was identified some decades ago. sweat urea concentration could reach 5.5 to 50 times the serum concentration . physical inactivity was reported as the fourth leading cause of death from chronic disease worldwide. warm water immersion (37-46◦c) increases limb blood flow, and muscle heating activates regulators of mitochondrial biogenesis. water immersion represent diffusion .the average person sweats between (0.8- 1.4) liters during an hour of exercise, drinking water represent water replacement . particularly, urea concentrations in sweat are persistently elevated in uremic patients. the 24-hour urinary urea excretion in summer was 1/4 the quantity in winter in uremic patients, indicating the compensatory urea excretion in sweat gland fluid . sweat glands are inactive except above 29°c, due to a concentration gradient within the stratum corneum, results in continuous water convection from within the body through the skin and into the environment. in our study we stimulate sweating of chronic kidney disease patients through mild physical activity as walking then they immersied in water to enhance waste excretion through skin.evaluation of these patients will be done through following up blood pressure,laboratory investigations as kidney function test sodium, potassium,phosphorus levels and uric acid.

Eligibility criteria:
inclusion criteria: chronic kidney disease group: 1. stage 3,4 2. age(18-60)yrs old. 3. not on dialysis. 4. without uremic symptoms nor standard indication for dialysis exclusion criteria: 1. history of cerebrovascular accidents. 2. history of advanced cardiac disease (heart failure, recent acute coronary syndrome, and cardiac arrhythmia). 3. active skin lesion 4. volume overload. 5- advanced liver cirrhosis, respiratory failure, and malignancy.
polyethylene glycol to improve sensation following digital nerve laceration

Conditions: Peripheral Nerve Injury; Nerve Injury

Summary: peg is a fusogen, a type of chemical that aids in mediating cell fusion. peg helps nerve cells recover neuronal continuity by removing plasmalemmal-bound water which opens the axonal ends on both sides of the injury. opening axonal ends permits the nerve ends to reconnect and begin regeneration. peg has been tested on animal models extensively and in earthworm models has been shown to induce fusion rates in 80-100% of neuronal cells. in crushed or severed mammalian sciatic nerves peg has enhanced neuronal continuity to baseline functioning levels. human applications for peg have been tested by bamba and colleagues in a case series with encouraging results. no studies, to our knowledge, have prospectively examined the use of peg in peripheral nerve injuries. we propose a placebo controlled, double-blinded randomized controlled trial to test the hypothesis that local peg administration can enhance sensory nerve regeneration following digital nerve transection compared to surgery alone.


Eligibility criteria:
inclusion criteria: * (1) surgery within twenty-four hours of injury (2) surgery completed in the minor procedures unit of the halifax infirmary. exclusion criteria: * (1) patients with cognitive impairment
feasibility study of a neuromuscular fatigue test and associated hemodynamic responses: application in healthy volunteers for use in patients with chemotherapy-treated breast cancer

Conditions: Fatigue; Muscle; Heart

Summary: this cross-sectional and single-center study aims to progressively induce an increase in peripheral fatigue during successive efforts in healthy subjects. participants will undergo three evaluations, each lasting one and half hours, to validate the test and assess its reproducibility. these three visits will be conducted at a minimum interval of 48 hours.


Eligibility criteria:
inclusion criteria: * man or woman * informed consent * age ≥ 18 years old * affiliation to a social security system * able to speak, read and understand french * practice physical activity 1 to 5 times per week, without reaching a level of intense training or high-level performance. exclusion criteria: * history of cancer * any known chronic pathology * protected minor or adult * psychiatric, musculoskeletal or neurological problems * implantation of a pacemaker * pregnant woman * presenting at least one contraindication to the use of transient blood flow occlusion
evaluate effectiveness of the biomet lumbar spinal fusion system

Conditions: Degenerative Disc Disease

Summary: the purpose of this study is to evaluate the effectiveness of the biomet lumbar spinal fusion system in patients undergoing lumbar fusion surgery.

all subjects enrolled in this study will receive the the biomet osteobiologic treatment system which is comprised of the spf® spine fusion stimulator and any or all of the following can be utilized in the study: any pedicle screw system, autograft and an interbody spacer

Eligibility criteria:
inclusion criteria: 1. the subject must, in the investigator's opinion, be psychosocially, mentally, and physically able to fully comply with this protocol including the required follow-up visits, the filling out of required forms, and have the ability to understand and give written informed consent. 2. the subject must be diagnosed with degenerative disc disease at up to 2 levels from l2-s1 inclusive and undergoing up to 2 level posterior lumbar spinal fusion surgery with or without anterior column fusion. 3. subjects must be between 18 and 75 years of age. 4. the patient must be skeletally mature (epiphyses closed). exclusion criteria: 1. subject is pregnant, lactating or interested in becoming pregnant during the duration of the study. 2. any active litigation. 3. subject is currently involved in another investigational study. 4. subject has a history (present or past) of substance abuse (recreational drugs, prescription drugs or alcohol) that in the investigator's opinion may interfere with protocol assessments and/or with the subject's ability to complete the protocol required follow-up. 5. subject is incarcerated. 6. more than 2 prior spine surgeries/revision surgeries or any previous spinal fusions at levels being currently treated. 7. traumatic instability. 8. any parathyroid or metabolic bone disease. 9. any active malignancy. 10. osteopenia/osteoporosis - all subjects will be screened for osteoporosis using score (simple calculated osteoporosis risk estimation) with a threshold value of 6. all subjects with a score value greater than 6 will be referred for dual-energy x-ray absorptiometry (dexa) scan. subjects with a t-score of £-1-2.5 will be excluded.

Keywords: spinal fusion degenerative disc disease
a study of c-car066 in subjects with r/r b cell lymphoma who received cd19 car-t therapy

Conditions: B Cell Lymphoma

Summary: this is a single-center, non-randomized clinical study to evaluate the safety and efficacy of c-car066 in treatment of r/r b cell lymphoma who received cd19 car-t therapy.

this study plans to enroll 10 patients to assess the safety and efficacy of c-car066. subjects who meet the eligibility criteria will receive a single dose of c-car066 injection. the study will include the following sequential phases: screening, pre- treatment (cell product preparation, lymphodepleting chemotherapy), c-car066 infusion and follow-up visit.

Eligibility criteria:
inclusion criteria: 1. the patient volunteered to participate in the study, and signed the informed consent 2. age 18-70 years old, male or female 3. patients with cd20+ dlbcl (including pmbcl and tfl), fl and mcl, at least one measurable lesion (ldi≥ 1.5 cm) 4. r/r lymphoma patients who received prior cd19 car-t therapy 5. at least one week from last treatment (radiation, chemotherapy, mab, etc) to apheresis 6. no immunosuppressive therapy was used within 1 week before c-car066 infusion 7. no mab treatment within 2 weeks before c-car066 infusion 8. adequate organ and bone marrow function 9. no contraindications of apheresis 10. expected survival time \> 3 months 11. ecog scores 0-1 exclusion criteria: 1. have a history of allergy to cellular products 2. patients with cardiac insufficiency classified as class iii or iv according to the new york heart association (nyha) heart function classification standard 3. a history of craniocerebral trauma, consciousness disorder, epilepsy, cerebral ischemia or hemorrhagic cerebrovascular disease 4. patients with active cns involvement 5. patients with autoimmune disease, immunodeficiency, or other treatment requiring immunosuppressor 6. severe active infection (except simple urinary tract, bacterial pharyngitis), or currently receiving intravenous antibiotics. however, prophylactic antibiotics, antiviral and antifungal treatments are allowed 7. live vaccination within 4 weeks before apheresis 8. hiv, hbv, hcv and tppa / rpr infections, and hbv carriers 9. have a history of alcoholism, drug addiction and mental illness 10. non-sterile subjects had any of the following: a) being pregnant / lactating; or b) having a pregnancy plan during the trial; or c) having fertility without taking effective contraception 11. patients with severe fludarabine or cyclophosphamide hypersensitivity 12. the patient has a history of other primary cancers, except for the following: 1. non-melanoma such as skin basal cell carcinoma cured by resection 2. cured carcinoma in situ such as cervical, bladder or breast cancer 13. the investigators believe that there are other circumstances that are not suitable for the trial

Keywords: b cell lymphoma received prior cd19 car-t therapy
pet imaging of ovarian carcinoma with 18f-fspg

Conditions: Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Cancer; Stage IIIA Primary Peritoneal Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Cancer; Stage IIIB Primary Peritoneal Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Cancer; Stage IIIC Primary Peritoneal Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Cancer; Stage IV Primary Peritoneal Cancer

Summary: this clinical trial studies positron emission tomography (pet) imaging utilizing 18f-fspg \[(s)-4-(3-\[18f\]fluoropropyl)-l-glutamic acid\], a glutamic acid derivative, to image patients with ovarian cancer before undergoing surgery or transplant. diagnostic procedures, such as 18f-fspg pet, may help find and diagnose ovarian cancer and find out how far the disease has spread.


Eligibility criteria:
inclusion criteria: * have a presumed diagnosis of advanced stage epithelial ovarian, fallopian tube, or peritoneal. * pelvic mass and/or omental caking with ca-125:cea ratio 25:1. * adequate performance status, ecog 0, 1, 2. * adequate organ function: * pcv \> 30 (with or without transfusion) * wbc: 3000 - 10,000 the lower level of normal for total wbcs is 4,000, but the nci considers levels of 3,000- 4,000 as mild suppression for drug trials, specifically not requiring treatment. * platelet count \> 150, 000 and \< 1,000,000 * cr \< 1.5 * lfts \< 1.5 x uln * have undergone or have agreed to undergo standard of care ct of the chest, abdomen, and pelvis. 18f-fspg pet imaging will be performed as investigational studies. * no prior treatment for ovarian cancer * have undergone or agree to undergo standard of care imaging for ovarian cancer with ct chest, abdomen, and pelvis. exclusion criteria: * have non-invasive or non-epithelial ovarian cancer on pathological confirmation. * pregnant and breastfeeding * poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dl). * other poorly controlled medical conditions that in the opinion of the surgeon, make them not a candidate for primary cytoreductive surgery. * ct of chest, abdomen, pelvis demonstrates: * any disease in the thoracic cavity \> 1 cm. * any suprarenal lymphadenopathy \> 1 cm. * liver metastases \> 1 cm. * disease in the porta hepatis or gallbladder fossa \> 1 cm. * pleural effusion \> 50% volume of the chest cavity on chest x-ray. * omental extension to the stomach, spleen, or lesser sac. * extension to the pelvic sidewall (this criteria may also be assessed on physical examination. * involvement of the root of the mesentery. * decline procedures that might be necessary for optimal primary cytoreduction (i.e. colostomy or splenectomy).
comparison of arpe prosthesis with the literature

Conditions: Arthritis

Summary: this study is designed to document the objective and subjective measurements after trapeziometacarpal athroplasty with arpe prosthesis and to compare those to literature values of outcome after trapeziectomy and trapeziectomy with ligament reconstruction and tendon interposition (lrti), as published in a recent meta-analysis.

the primary objective is to compare functional outcome at 3 years after trapezio-metarcarpal arthroplasty with trapeziectomy and trapeziectomy with ligament reconstruction and tendon interposition. literature values obtained by a recently published meta analysis will be used. the secondary objectives are: * to compare functional outcome at 1 and at 5 years after trapezio-metarcarpal arthroplasty with trapeziectomy and trapeziectomy with ligament reconstruction and tendon interposition * to determine pre- and post-operative hr qol * incidence of radiolucencies at each follow up time point. literature values from the same meta analysis will be used, patients will be assessed at preoperatively, and at 1, 3 and 5 years postoperatively. measured outcomes: grip strength, tip pinch strength, key pinch strength, pain, occurrence of adverse events, hand function.

Eligibility criteria:
inclusion/exclusion criteria are identical to those indications and contraindications stated in the package insert of the implant. inclusion criteria: * patients with trapezio-metacarpal arthritis eaton stage of trapezio-metacarpal arthritis: stage ii - iv * patients willing to return for follow up evaluation. exclusion criteria: * local or systemic infections * severe muscular, neurological or vascular deficiencies of the extremity involved * bone destruction or poor bone to affect implant stability * allergy to any of the components of the implant

Keywords: arthroplasty trapezio-metacarpial
a study to compare qls1128 with placebo in symptomatic participants with mild to moderate covid-19

Conditions: COVID-19

Summary: a phase 3 study to evaluate the efficacy and safety of qls1128 orally in symptomatic participants with mild to moderate covid-19


Eligibility criteria:
inclusion criteria: 1. male or female subjects between ages of 18-80 years. 2. confirmed sars-cov-2 infection as determined by rt-pcr or antigen test in any specimen collected within 120 hours prior to randomization. 3. initial onset of the covid-19-related symptoms/signs within 48 hours prior to the randomization,and any of the following conditions are met on the day of randomization. 1. score ≥2 for at least one symptom of body pain or muscle pain, headache,stuffy or runny nose,sore throat,cough,shortness of breath or difficulty breathing. 2. risk factors associated with progression to severe/critical covid-19 with a score ≥1 for at least one symptom of fever,muscle or body pain, headache,stuffy or runny nose,sore throat,cough,shortness of breath or difficulty breathing. 3. score ≥1 for fever,with a score ≥1 for at least one symptom of muscle or body pain,headache,stuffy or runny nose,sore throat,cough,shortness of breath or difficulty breathing. exclusion criteria: 1. previous treatment with qls1128 sustained-release tablets or other 3cl protease inhibitors failed. 2. has received vaccines within 28 days prior to screening or planned to receive vaccines during the study period (including but not limited to covid-19 vaccine). 3. those who have a history of sars-cov-2 infection and still have symptoms related to covid-19 during the screening period. 4. a history of sars-cov-2 infection, and the time of diagnosis of the latest infection to the time of diagnosis of the current infection is not more than 28 days. 5. has received local approved anti-sars-cov-2 drugs within 7 days before screening or plan to receive them during the study period. 6. has received monoclonal antibody against sars-cov-2 virus within 1 year prior to screening. 7. has received convalescent plasma therapy for covid-19 patients or expect to receive convalescent plasma therapy for covid-19 patients during the trial. 8. has received any cyp3a4/2c8 strong inducer within 14 days prior to screening or plan to receive any cyp3a4/2c8 strong inducer during the study period. 9. a known history of active liver disease , including acute/chronic hepatitis b, hepatitis c, cirrhosis, or acute liver failure. 10. allergic or have contraindications to test drugs or test drug excipients.